Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT06989723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT06989723
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06989723. Randomized; double masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Condition
- Fatty Liver
- Intervention (Drug)
- Pioglitazone 15 MG [Actos]
- Intervention (Drug)
- Empagliflozin 10 MG [Jardiance]
- Intervention (Drug)
- Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
- Lead sponsor
- Seoul National University Bundang Hospital
- Collaborator
- Celltrion
Record details
- Record id
cardio:ct-nct06989723- Content hash
5aa4aeb0b36e06735329a586e7649eda37614f6e19337d1d5c257b2bd2e6eceb